Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Exploring a role for heteromerization in GPCR signalling specificity.

Rozenfeld R, Devi LA.

Biochem J. 2011 Jan 1;433(1):11-8. doi: 10.1042/BJ20100458. Review.

2.

Increased abundance of opioid receptor heteromers after chronic morphine administration.

Gupta A, Mulder J, Gomes I, Rozenfeld R, Bushlin I, Ong E, Lim M, Maillet E, Junek M, Cahill CM, Harkany T, Devi LA.

Sci Signal. 2010 Jul 20;3(131):ra54. doi: 10.1126/scisignal.2000807.

3.
4.

Acute pharmacological modulation of mGluR8 reduces measures of anxiety.

Duvoisin RM, Pfankuch T, Wilson JM, Grabell J, Chhajlani V, Brown DG, Johnson E, Raber J.

Behav Brain Res. 2010 Oct 15;212(2):168-73. doi: 10.1016/j.bbr.2010.04.006.

5.

Receptor heteromerization and drug discovery.

Rozenfeld R, Devi LA.

Trends Pharmacol Sci. 2010 Mar;31(3):124-30. doi: 10.1016/j.tips.2009.11.008.

6.

Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation.

Ma L, Seager MA, Wittmann M, Jacobson M, Bickel D, Burno M, Jones K, Graufelds VK, Xu G, Pearson M, McCampbell A, Gaspar R, Shughrue P, Danziger A, Regan C, Flick R, Pascarella D, Garson S, Doran S, Kreatsoulas C, Veng L, Lindsley CW, Shipe W, Kuduk S, Sur C, Kinney G, Seabrook GR, Ray WJ.

Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15950-5. doi: 10.1073/pnas.0900903106. Erratum in: Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):18040. Seager, Matthew [corrected to Seager, Matthew A].

7.

Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation.

Han Y, Moreira IS, Urizar E, Weinstein H, Javitch JA.

Nat Chem Biol. 2009 Sep;5(9):688-95. doi: 10.1038/nchembio.199.

8.

G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function.

Milligan G.

Br J Pharmacol. 2009 Sep;158(1):5-14. doi: 10.1111/j.1476-5381.2009.00169.x. Review.

9.

The apparent cooperativity of some GPCRs does not necessarily imply dimerization.

Chabre M, Deterre P, Antonny B.

Trends Pharmacol Sci. 2009 Apr;30(4):182-7. doi: 10.1016/j.tips.2009.01.003. Review.

PMID:
19269046
10.

Cell surface targeting of mu-delta opioid receptor heterodimers by RTP4.

Décaillot FM, Rozenfeld R, Gupta A, Devi LA.

Proc Natl Acad Sci U S A. 2008 Oct 14;105(41):16045-50. doi: 10.1073/pnas.0804106105.

11.

Conformational cross-talk between alpha2A-adrenergic and mu-opioid receptors controls cell signaling.

Vilardaga JP, Nikolaev VO, Lorenz K, Ferrandon S, Zhuang Z, Lohse MJ.

Nat Chem Biol. 2008 Feb;4(2):126-31. doi: 10.1038/nchembio.64.

PMID:
18193048
12.
14.

Inhibition of tolerance to spinal morphine antinociception by low doses of opioid receptor antagonists.

McNaull B, Trang T, Sutak M, Jhamandas K.

Eur J Pharmacol. 2007 Apr 10;560(2-3):132-41.

PMID:
17307158
15.

Allosteric modulation of G protein-coupled receptors.

May LT, Leach K, Sexton PM, Christopoulos A.

Annu Rev Pharmacol Toxicol. 2007;47:1-51. Review.

PMID:
17009927
16.
17.

Heterodimerization of g protein-coupled receptors: specificity and functional significance.

Prinster SC, Hague C, Hall RA.

Pharmacol Rev. 2005 Sep;57(3):289-98. Review.

18.

Odorant receptor heterodimerization in the olfactory system of Drosophila melanogaster.

Neuhaus EM, Gisselmann G, Zhang W, Dooley R, Störtkuhl K, Hatt H.

Nat Neurosci. 2005 Jan;8(1):15-7.

PMID:
15592462
20.

Allosteric modulation of G protein-coupled receptors: perspectives and recent developments.

Soudijn W, Van Wijngaarden I, IJzerman AP.

Drug Discov Today. 2004 Sep 1;9(17):752-8. Review.

PMID:
15450241
Items per page

Supplemental Content

Support Center